Carilion Clinic Further Expands Quality Cardiac Care Access with Latest Philips Innovations at New Regional Cardiovascular Institute in Virginia, US

Integrated Philips cardiovascular solutions enhance the patient & staff experience with reduced X-ray dose & procedure time for more time with patients and to help improve outcomes. New facility will have 11 specialized Philips interventional suites, allowing physicians to treat patients with complex cardiovascular conditions closer to home.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Carilion Clinic, a not-for-profit health care organization serving more than one million people in the States of Virginia and West Virginia, today announced Carilion Clinic will adopt the Philips cardiovascular care ecosystem of solutions at the future home of its Cardiovascular Institute at Crystal Spring Tower.

Carilion’s new facility will have 11 specialized Philips interventional suites, allowing physicians to treat patients with complex cardiovascular conditions closer to home while optimizing the clinical, operational and overall performance of the health system’s cardiovascular service line. This investment illustrates Carilion’s commitment to empowering its clinicians with innovative technology to provide quality care for its communities.

Carilion’s comprehensive hospital network, primary and specialty physician practices and other complementary services deliver high-quality, patient-centered care. The flagship hospital, Carilion Roanoke Memorial Hospital, totals 718 beds. The Carilion Clinic Cardiovascular Institute will relocate to this new facility and provide state-of-the art heart, lung and vascular services to the region. Services include inpatient nursing care, cardiovascular ORs, cardiac catheterization and electrophysiology labs.

Along with caring for the local community, Carilion Roanoke Memorial Hospital is the major referral center and only Level 1 Trauma Center for patients in the region who require specialized medical care. It also has the only hybrid operating rooms available in Southwest Virginia. Equipped with these new Philips solutions, the highly skilled medical staff will be able to continue handling complex cases or procedures that may not be available at surrounding healthcare facilities.

“At Carilion Clinic, we are committed to improving the health of the communities we serve. We know that collaboration is an essential component to realizing this vision,” said Marguerite Underwood, Vice President for the Carilion Clinic Cardiovascular Institute. “Working with Philips ensures that we will be able to set the standard in cardiovascular care, not only today, but well into the future.”

The new labs are the foundation of the integrated Philips ecosystem of solutions for cardiovascular care and include the Philips Azurion Image-Guided Therapy System, along with EPIQ CVx cardiology ultrasound system with ultrasound enabled AI capabilities, IntraSight with SyncVision for IVUS imaging and physiology and interventional tools. Together, the technology provides exceptional imaging with reduced X-ray dose [1], improved workflow and more efficient turnaround times [2], offering a high level of clinical confidence. A service program will reduce maintenance complexity, keeping systems up to date with the latest software. Furthermore, Carilion will be able to leverage ongoing clinical education for its staff.

“For many years, Carilion has been recognized for delivering exceptional cardiac care. Maintaining the highest standard of care means continuous growth and innovation, making healthcare delivery more efficient and effective,” said Jeff DiLullo, Chief Region Leader, Philips North America. “The Crystal Spring Tower expansion illustrates Carilion’s commitment to its staff and patients, giving clinicians access to world-class technology while providing a level of care not available anywhere else in the region.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”